Search Results - "drug development"

SCID mouse model of psoriasis: A unique tool for drug development of autoreactive T-cell and TH-17 cell-mediated autoimmune diseases by Raychaudhuri Smriti, Raychaudhuri Siba

Connect to this object online.

Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug Development by Kayla Ann Andrews, Joel S. Owen, James McCarthy, David Wesche, Nathalie Gobeau, Thaddeus H. Grasela, Jörg J. Möhrle

Connect to this object online.

Sabatolimab (MBG453) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors by Siyan Xu, Na Zhang, Mikael L. Rinne, Haiying Sun, Andrew M. Stein

Connect to this object online.

A case study of a patient‐centered reverse translational systems‐based approach to understand adverse event profiles in drug development by Sarah Kim, Gezim Lahu, Majid Vakilynejad, Theodoros G. Soldatos, David B. Jackson, Lawrence J. Lesko, Mirjam N. Trame

Connect to this object online.

Investigating the current state of the Russian market for drugs treating infectious and inflammatory conditions of oral cavity and oropharynx to demonstrate the need for new drug development by V. I. Zvereva, D. R. Dzhavakhyan, V. N. Dul, V. S. Bobyleva, A. A. Markaryan, E. I. Morkovin, D. V. Kurkin, M. A. Dzhavakhyan

Connect to this object online.

Minimal Physiologically-Based Pharmacokinetic (mPBPK) Metamodeling of Target Engagement in Skin Informs Anti-IL17A Drug Development in Psoriasis by Vivaswath S. Ayyar, Jong Bong Lee, Weirong Wang, Meghan Pryor, Yanli Zhuang, Thomas Wilde, An Vermeulen, An Vermeulen

Connect to this object online.

The use of complex marketing analysis and QSPR methodology for the necessity of a drug development grounding for the treatment of type 2 diabetes mellitus with increased bioavailability by Inna Kovalevska, Olena Ruban, Alina Volkova, Alla Kotvitska, Alina Cherkashyna

Connect to this object online.

Protein Translation Enzyme lysyl-tRNA Synthetase Presents a New Target for Drug Development against Causative Agents of Loiasis and Schistosomiasis. by Arvind Sharma, Manmohan Sharma, Manickam Yogavel, Amit Sharma

Connect to this object online.

Functional Proteins Involved in Regulation of Intracellular Ca2+ for Drug Development: Role of Calcium/Calmodulin-Dependent Protein Kinases in Ischemic Neuronal Death by Shigetoshi Yano, Motohiro Morioka, Jun-ichi Kuratsu, Kohji Fukunaga

Connect to this object online.

Exploring the pharmacological potential of Lepionurus sylvestris blume: from folklore medicinal usage to modern drug development strategies using in vitro and in silico analyses by Laldinfeli Ralte, Hmingremhlua Sailo, Nachimathu Senthil Kumar, Y. Tunginba Singh

Connect to this object online.

Systematic analysis of randomised controlled trials of Chinese herb medicine for non-alcoholic steatohepatitis (NASH): implications for future drug development and trial design by Xianwen Chen, Junnan Shi, Yunfeng Lai, Yan Xue, Carolina Oi Lam Ung, Hao Hu

Connect to this object online.

Model‐informed drug development of autologous CAR‐T cell therapy: Strategies to optimize CAR‐T cell exposure leveraging cell kinetic/dynamic modeling by Anna M. Mc Laughlin, Peter A. Milligan, Cassian Yee, Martin Bergstrand

Connect to this object online.

Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae by Xi-Wei Ji, Xiao Zhu, Yun Li, Feng Xue, Isabelle Hui San Kuan, Isabelle Hui San Kuan, Qing-Feng He, Xiang-Rui Meng, Xiao-Qiang Xiang, Yi-Min Cui, Bo Zheng

Connect to this object online.

A Focus Group Study about Oral Drug Administration Practices at Hospital Wards-Aspects to Consider in Drug Development of Age-Appropriate Formulations for Children by Maria Rautamo, Kirsi Kvarnström, Mia Sivén, Marja Airaksinen, Pekka Lahdenne, Niklas Sandler

Connect to this object online.

Nuclear Receptors as Targets for Drug Development: Molecular Mechanisms for Regulation of Obesity and Insulin Resistance by Peroxisome Proliferator-Activated Receptor , CREB-Binding Protein, and Adiponectin by Atsushi Tsuchida, Toshimasa Yamauchi, Takashi Kadowaki

Connect to this object online.

Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? by Francesca Negri, Camillo Porta

Connect to this object online.

Nuclear Receptors as Targets for Drug Development: Crosstalk Between Peroxisome Proliferator-Activated Receptor γ and Cytokines in Bone Marrow-Derived Mesenchymal Stem Cells by Ichiro Takada, Miyuki Suzawa, Shigeaki Kato

Connect to this object online.

Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug development by Paul van den Berg, Wei Gao, Maurice J. Ahsman, Leticia Arrington, Filippos Kesisoglou, Randy Miller, Teun M. Post, Matthew L. Rizk

Connect to this object online.

Model‐informed drug development for immuno‐oncology agonistic anti‐GITR antibody GWN323: Dose selection based on MABEL and biologically active dose by Yan Ji, Deborah Knee, Xinhui Chen, Anhthu Dang, Jennifer Mataraza, Babette Wolf, Sherwin K. B. Sy

Connect to this object online.

Functional Proteins Involved in Regulation of Intracellular Ca2+ for Drug Development: The Extracellular Calcium Receptor and an Innovative Medical Approach to Control Secondary Hyperparathyroidism by Calcimimetics by Nobuo Nagano, Edward F. Nemeth

Connect to this object online.